Organon & Co.

    Jurisdiction
    United States
    ISIN
    US68622V1061 (OGN)
    Sectors
    1. Healthcare
    2. Drug Manufacturers - General

    Scores

    Fair value (Benjamin Graham formula)
    €43.37 422.6% undervalued
    Financial strength (Piotroski F-Value)
    5 / 9
    Fundamental strength relative to industry (Mohanram G-Value)
    1 / 7

    Profile

    Organon & Co., a health care company, develops and delivers health solutions through a portfolio of prescription therapies in the United States and internationally. Read full profile

    Fundamentals

    Net revenue
    €5.36B
    Gross margin
    56.3%
    EBIT
    €1.14B
    EBIT margin
    21.3%
    Net income
    €597.07M
    Net margin
    11.1%

    Statement period: - (published )

    Estimates

    Fiscal Year Net revenue Net income
    €5.41B +0.9% €911.03M +52.6%
    €5.47B +1.2% €939.17M +3.1%
    €5.67B +3.5% €1.01B +7.3%

    Stock price

    Stock price loading... No stock price available Stock price provided by Lang & Schwarz Steigende Zinsen und niedrigere Bewertungen für Wachstumsaktien im Allgemeinen Eine Gewinnwarnung beim Konkurrenten Adyen signalisiert eine Abkühlung des europäischen Markts für Zahlungsdienstleistungen. Eine Gewinnwarnung von Wordline SA triggert einen massiven Kursverlust.

    Configure chart

    Adjust colors to be more accessible for red-green-colorblind users.
    Scale
    Moving average Display a moving average line on the chart.

    Dividends

    Last dividend amount
    $0.02
    Ex date
    Payment date
    Dividend payout ratio
    41.4%

    Analyst ratings

    No analyst ratings available

    Insider Transactions

    No insider transactions in the last 90 days. View older insider transactions

    Earnings Calls

    Investor transactions

    Name Shares Value Last change Change type
    Ray Dalio 68K $1.02M +50K Buy

    Earnings Calls

    Latest earnings call: August 5, 2025 (Q2 2025)

    Add to watchlist

    Notifications